Positron emission tomography tracers for imaging angiogenesis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue SUPPL. 1, 2010, Pages

  Haubner, Roland ^a   Beer, Ambros J ^b   Wang, Hui ^c   Chen, Xiaoyuan ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c SICHUAN UNIVERSITY   (China)

^d NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Angiogenesis; Fibronectin ED B domain; Imaging; Integrin v 3; Matrix metalloproteinase; Positron emission tomography; Vascular endothelial growth factor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID VASCULOTROPIN 121 CU 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID VASCULOTROPIN DEE CU 64; 3,4,6 TRI O ACETYL 2 DEOXY 2 FLUOROGLUCOPYRANOSYL PHENYLTHIOSULFONATE F 18; 4 FLUOROBENZALDEHYDE F 18; 4 FLUOROBENZYLIDENEHYDRAZONE 6 NICOTINAMIDE C F 18; AH 111585 F 18; ARGINYLGLYCYLASPARTIC ACID; BEVACIZUMAB; BEVACIZUMAB ZR 89; FIBRONECTIN; FLUCICLATIDE F 18; FLUOROSILYL BENZALDEHYDE F 18; GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; GELATINASE A; GELATINASE B; GUANIDINOBENZOYL HYDRAZINO OXOPENTANOIC ACID; HYNIC ARGINYLGLYCYLASPARTIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N [2 (4 FLUOROBENZAMIDO)ETHYL]MALEIMIDE F 18; NC 100717; NC 100717 TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 121 CU 64; VASCULOTROPIN RECEPTOR; VASCULOTROPIN TC 99M; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR ANTAGONIST;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER DIAGNOSIS; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG UPTAKE; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; TREATMENT PLANNING; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

EID: 77956267966     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1503-4     Document Type: Review

References (144)

1. D Creamer D Sullivan R Bicknell J Barker 2002 Angiogenesis in psoriasis Angiogenesis 5 231 236 1:CAS:528:DC%2BD3sXltFynsLk%3D 12906316
2. GG Bishop JA McPherson JM Sanders SE Hesselbacher MJ Feldman CA McNamara, et al. 2001 Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit Circulation 103 1906 1911 1:CAS:528:DC%2BD3MXjsFGgsbc%3D 11294811
3. CM Storgard DG Stupack A Jonczyk SL Goodman RI Fox DA Cheresh 1999 Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist J Clin Invest 103 47 54 1:CAS:528:DyaK1MXjsl2msQ%3D%3D 9884333 See comment J Clin Invest 1999;103:3-4
4. E Chavakis B Riecke J Lin T Linn RG Bretzel KT Preissner, et al. 2002 Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides Diabetologia 45 262 267 1:CAS:528:DC%2BD38Xhs1enu7c%3D 11935158
5. J Folkman 2002 Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 6 Suppl 16 15 18 1:CAS:528:DC%2BD3sXlvFSqtg%3D%3D 12516034
6. S Loges C Roncal P Carmeliet 2009 Development of targeted angiogenic medicine J Thromb Haemost 7 21 33 1:CAS:528:DC%2BD1MXitFCms74%3D 18983480
7. LM Ellis W Liu F Fan YD Jung N Reinmuth O Stoeltzing, et al. 2002 Synopsis of angiogenesis inhibitors in oncology Oncology (Williston Park) 16 14 22
8. M Kuwano J Fukushi M Okamoto A Nishie H Goto T Ishibashi, et al. 2001 Angiogenesis factors Intern Med 40 565 572 1:CAS:528:DC%2BD3MXntFGgt7Y%3D 11506294
9. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 249 257 1:CAS:528:DC%2BD3cXmvVSls74%3D 11001068
10. M Hagedorn A Bikfalvi 2000 Target molecules for anti-angiogenic therapy: from basic research to clinical trials Crit Rev Oncol Hematol 34 89 110 1:STN:280:DC%2BD3c3mtFensQ%3D%3D 10799835
11. P Vihinen VM Kähäri 2002 Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets Int J Cancer 99 157 166 1:CAS:528:DC%2BD38XivFyrsr4%3D 11979428
12. JE Rundhaug 2005 Matrix metalloproteinases and angiogenesis J Cell Mol Med 9 267 285 1:CAS:528:DC%2BD2sXlvFCluro%3D 15963249
13. RO Hynes BL Bader K Hodivala-Dilke 1999 Integrins in vascular development Braz J Med Biol Res 32 501 510 1:CAS:528:DyaK1MXjvVKnu7w%3D 10412560
14. BP Eliceiri DA Cheresh 2000 Role of alpha v integrins during angiogenesis Cancer J 6 Suppl 3 S245 S249 1:STN:280:DC%2BD3cvptlyltQ%3D%3D 10874494
15. PC Brooks AM Montgomery M Rosenfeld RA Reisfeld T Hu G Klier, et al. 1994 Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1157 1164 1:CAS:528: DyaK2MXivVWqu7o%3D 7528107
16. PC Brooks S Strömblad R Klemke D Visscher FH Sarkar DA Cheresh 1995 Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin J Clin Invest 96 1815 1822 1:CAS:528:DyaK2MXosFyhtr8%3D 7560073 See comment J Clin Invest 1995;96:1696-7
17. HP Hammes M Brownlee A Jonczyk A Sutter KT Preissner 1996 Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization Nat Med 2 529 533 1:CAS:528: DyaK28Xislyhsrk%3D 8616710
18. RO Hynes 2002 A reevaluation of integrins as regulators of angiogenesis Nat Med 8 918 921 1:CAS:528:DC%2BD38Xms1ais7g%3D 12205444
19. GD Yancopoulos S Davis NW Gale JS Rudge SJ Wiegand J Holash 2000 Vascular-specific growth factors and blood vessel formation Nature 407 242 248 1:CAS:528:DC%2BD3cXmvVSlsrY%3D 11001067
20. L Rosen 2000 Antiangiogenic strategies and agents in clinical trials Oncologist 5 Suppl 1 20 27 1:CAS:528:DC%2BD3cXjsFartrs%3D 10804087
21. G Gasparini R Longo M Toi N Ferrara 2005 Angiogenic inhibitors: a new therapeutic strategy in oncology Nat Clin Pract Oncol 2 562 577 1:CAS:528:DC%2BD2MXht1Ghu77F 16270097
22. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 795 803 1:CAS:528:DC%2BD38XnsVGrtbk%3D 12360282
23. JM Roodhart MH Langenberg E Witteveen EE Voest 2008 The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 132 143 1:CAS:528:DC%2BD1cXpvVGntrY%3D 18690886
24. TL Underiner JP Mallamo J Singh 2002 Syntheses of C12,N13 heterocyclic bridged fused indenopyrrolocarbazoles J Org Chem 67 3235 3241 1:CAS:528:DC%2BD38XivVOmtL8%3D 12003530
25. N Ferrara 2004 Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 581 611 1:CAS:528:DC%2BD2cXns1Ght74%3D 15294883
26. AR Hsu X Chen 2008 Advances in anatomic, functional, and molecular imaging of angiogenesis J Nucl Med 49 511 514 18375921
27. WB Nagengast EG de Vries GA Hospers NH Mulder JR de Jong H Hollema, et al. 2007 In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft J Nucl Med 48 1313 1319 1:CAS:528:DC%2BD2sXhtVSktb%2FE 17631557
28. JE Park GA Keller N Ferrara 1993 The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 1317 1326 1:CAS:528:DyaK2cXitlOjur0%3D 8167412
29. F Yuan Y Chen M Dellian N Safabakhsh N Ferrara RK Jain 1996 Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody Proc Natl Acad Sci U S A 93 14765 14770 1:CAS:528:DyaK28XnsVOht78%3D 8962129
30. Y Wang D Fei M Vanderlaan A Song 2004 Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro Angiogenesis 7 335 345 1:CAS:528:DC%2BD2MXktVajtL4%3D 15886877
31. DR Collingridge VA Carroll M Glaser EO Aboagye S Osman OC Hutchinson, et al. 2002 The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography Cancer Res 62 5912 5919 1:CAS:528:DC%2BD38XotFyktLo%3D 12384557
32. GC Jayson J Zweit A Jackson C Mulatero P Julyan M Ranson, et al. 2002 Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies J Natl Cancer Inst 94 1484 1493 1:CAS:528:DC%2BD38XosVans7k%3D 12359857
33. MG Scheer TH Stollman OC Boerman K Verrijp FC Sweep WP Leenders, et al. 2008 Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression Eur J Cancer 44 1835 1840 1:CAS:528:DC%2BD1cXhtVamt7rL 18632262
34. G Niu X Chen 2009 PET imaging of angiogenesis PET Clin 4 17 38 20046926
35. E Lu WR Wagner U Schellenberger JA Abraham AL Klibanov SR Woulfe, et al. 2003 Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue Circulation 108 97 103 1:CAS:528:DC%2BD3sXkvFyjtLk%3D 12821549
36. FG Blankenberg S Mandl YA Cao C O'Connell-Rodwell C Contag C Mari, et al. 2004 Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor J Nucl Med 45 1373 1380 1:CAS:528: DC%2BD2cXnsFSmu7s%3D 15299064
37. S Li M Peck-Radosavljevic O Kienast J Preitfellner G Hamilton A Kurtaran, et al. 2003 Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy Ann Oncol 14 1274 1277 1:STN:280:DC%2BD3szkvVaqtQ%3D%3D 12881392
38. S Li M Peck-Radosavljevic O Kienast J Preitfellner E Havlik W Schima, et al. 2004 Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma Q J Nucl Med Mol Imaging 48 198 206 1:STN:280:DC%2BD2crivVejsg%3D%3D 15499293
39. S Li M Peck-Radosavljevic E Koller F Koller K Kaserer A Kreil, et al. 2001 Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy Int J Cancer 91 789 796 1:CAS:528:DC%2BD3MXhsFGjtr8%3D 11275981
40. W Cai K Chen KA Mohamedali Q Cao SS Gambhir MG Rosenblum, et al. 2006 PET of vascular endothelial growth factor receptor expression J Nucl Med 47 2048 2056 1:CAS:528:DC%2BD2sXksFKmsA%3D%3D 17138749
41. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000;275:26690-5.
42. FG Blankenberg MV Backer Z Levashova V Patel JM Backer 2006 In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF Eur J Nucl Med Mol Imaging 33 841 848 16699765
43. MV Backer Z Levashova V Patel BT Jehning K Claffey FG Blankenberg, et al. 2007 Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes Nat Med 13 504 509 1:CAS:528:DC%2BD2sXjvVaqtbo%3D 17351626
44. BA Keyt HV Nguyen LT Berleau CM Duarte J Park H Chen, et al. 1996 Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis J Biol Chem 271 5638 5646 1:CAS:528:DyaK28XhsFehtrw%3D 8621427
45. H Wang W Cai K Chen ZB Li A Kashefi L He, et al. 2007 A new PET tracer specific for vascular endothelial growth factor receptor 2 Eur J Nucl Med Mol Imaging 34 2001 2010 1:CAS:528:DC%2BD2sXhtlyiurrP 17694307
46. Z Levashova M Backer JM Backer FG Blankenberg 2008 Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m Bioconjug Chem 19 1049 1054 1:CAS:528:DC%2BD1cXksFyktrs%3D 18407683
47. W Cai R Guzman AR Hsu H Wang K Chen G Sun, et al. 2009 Positron emission tomography imaging of poststroke angiogenesis Stroke 40 270 277 18948613
48. M Rodriguez-Porcel W Cai O Gheysens JK Willmann K Chen H Wang, et al. 2008 Imaging of VEGF receptor in a rat myocardial infarction model using PET J Nucl Med 49 667 673 18375924
49. FG Blankenberg Z Levashova SK Sarkar J Pizzonia MV Backer JM Backer 2010 Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study Transl Oncol 3 56 64 20165696
50. R Hynes 1985 Molecular biology of fibronectin Annu Rev Cell Biol 1 67 90 1:CAS:528:DyaL28XjtVCrsg%3D%3D 3916323
51. P Castellani A Dorcaratto A Pau M Nicola A Siri B Gasparetto, et al. 2000 The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas Acta Neurochir (Wien) 142 277 282 1:STN:280:DC%2BD3c3nslersQ%3D%3D
52. D Neri B Carnemolla A Nissim A Leprini G Querzè E Balza, et al. 1997 Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform Nat Biotechnol 15 1271 1275 1:CAS:528:DyaK2sXntVSlurk%3D 9359110
53. L Tarli E Balza F Viti L Borsi P Castellani D Berndorff, et al. 1999 A high-affinity human antibody that targets tumoral blood vessels Blood 94 192 198 1:CAS:528:DyaK1MXktlOks74%3D 10381513
54. M Santimaria G Moscatelli GL Viale L Giovannoni G Neri F Viti, et al. 2003 Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer Clin Cancer Res 9 571 579 1:CAS:528:DC%2BD3sXhtVKksrs%3D 12576420
55. L Borsi E Balza M Bestagno P Castellani B Carnemolla A Biro, et al. 2002 Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int J Cancer 102 75 85 1:CAS:528:DC%2BD38XnvFCru7g%3D 12353237
56. D Berndorff S Borkowski S Sieger A Rother M Friebe F Viti, et al. 2005 Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate Clin Cancer Res 11 7053s 7063s 1:CAS:528:DC%2BD2MXhtVKiurjE 16203802
57. R Rossin D Berndorff M Friebe LM Dinkelborg MJ Welch 2007 Small-animal PET of tumor angiogenesis using a (76)Br-labeled human recombinant antibody fragment to the ED-B domain of fibronectin J Nucl Med 48 1172 1179 1:CAS:528:DC%2BD2sXhtVertL%2FM 17574989
58. BM Tijink LR Perk M Budde M Stigter-van Walsum GW Visser RW Kloet, et al. 2009 (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy Eur J Nucl Med Mol Imaging 36 1235 1244 19259661
59. S Curran GI Murray 2000 Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis Eur J Cancer 36 1621 1630 1:CAS:528:DC%2BD3cXlvFSrs7Y%3D 10959048
60. M Hidalgo SG Eckhardt 2001 Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 178 193 1:CAS:528: DC%2BD3MXhtlKiurw%3D 11158186
61. DE Gomez DF Alonso H Yoshiji UP Thorgeirsson 1997 Tissue inhibitors of metalloproteinases: structure, regulation and biological functions Eur J Cell Biol 74 111 122 1:CAS:528:DyaK2sXmslSqsLg%3D 9352216
62. HD Foda S Zucker 2001 Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis Drug Discov Today 6 478 482 1:CAS:528: DC%2BD3MXjtlCjsb4%3D 11344033
63. H Iwata S Kobayashi H Iwase A Masaoka N Fujimoto Y Okada 1996 Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas Jpn J Cancer Res 87 602 611 1:CAS:528:DyaK28XjvVOit7c%3D 8766524
64. M Nguyen J Arkell CJ Jackson 2001 Human endothelial gelatinases and angiogenesis Int J Biochem Cell Biol 33 960 970 1:CAS:528:DC%2BD3MXlt1Sisb0%3D 11470230
65. A Matter 2001 Tumor angiogenesis as a therapeutic target Drug Discov Today 6 1005 1024 1:CAS:528:DC%2BD3MXntVyls7w%3D 11576867
66. E Koivunen W Arap H Valtanen A Rainisalo OP Medina P Heikkilä, et al. 1999 Tumor targeting with a selective gelatinase inhibitor Nat Biotechnol 17 768 774 1:CAS:528:DyaK1MXmtFaiurc%3D 10429241
67. B Kuhnast C Bodenstein R Haubner HJ Wester R Senekowitsch-Schmidtke M Schwaiger, et al. 2004 Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide Nucl Med Biol 31 337 344 1:CAS:528:DC%2BD2cXitFeitLg%3D 15028246
68. DE Levy F Lapierre W Liang W Ye CW Lange X Li, et al. 1998 Matrix metalloproteinase inhibitors: a structure-activity study J Med Chem 41 199 223 1:CAS:528:DyaK1cXptFGl 9457244
69. R Kiyama Y Tamura F Watanabe H Tsuzuki M Ohtani M Yodo 1999 Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors J Med Chem 42 1723 1738 1:CAS:528:DyaK1MXisFGntrg%3D 10346925
70. V Pelmenschikov PE Siegbahn 2002 Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study Inorg Chem 41 5659 5666 1:CAS:528:DC%2BD38Xms1Ojt7s%3D 12401069
71. V Aranapakam JM Davis GT Grosu J Baker J Ellingboe A Zask, et al. 2003 Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis J Med Chem 46 2376 2396 1:CAS:528:DC%2BD3sXjs12ksL4%3D 12773042
72. S Furumoto R Iwata T Ido 2002 Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imaging J Labelled Comp Radiopharm 45 975 986 1:CAS:528:DC%2BD38XptVenu7Y%3D
73. B Kuhnast C Bodenstein HJ Wester WA Weber 2003 Carbon-11 labelling of an N-sulfonylamino acid derivative: a potential tracer for MMP-2 and MMP-9 imaging J Labelled Comp Radiopharm 46 1093 1103 1:CAS:528:DC%2BD3sXps1OjtbY%3D
74. X Fei QH Zheng GD Hutchins X Liu KL Stone KA Carlson, et al. 2002 Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents J Labelled Comp Radiopharm 45 449 470 1:CAS:528:DC%2BD38XksVWrtr0%3D
75. X Fei Q-H Zheng X Liu J-Q Wang KL Stone KD Miller, et al. 2003 Synthesis of MMP inhibitor radiotracer [11C]CGS 25966, a new potential PET tumor imaging agent J Labelled Comp Radiopharm 46 343 351 1:CAS:528:DC%2BD3sXjt1Wms74%3D
76. QH Zheng X Fei TR DeGrado JQ Wang K Lee Stone TD Martinez, et al. 2003 Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl] sulfonylamino]-3-methylbutyric acid [(11)C]methyl ester Nucl Med Biol 30 753 760 1:CAS:528:DC%2BD3sXnt1Gku7w%3D 14499334
77. QH Zheng X Fei X Liu JQ Wang H Bin Sun BH Mock, et al. 2002 Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents Nucl Med Biol 29 761 770 1:CAS:528:DC%2BD38XnvVKmt7w%3D 12381456
78. X Fei QH Zheng X Liu JQ Wang HB Sun BH Mock, et al. 2003 Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents Bioorg Med Chem Lett 13 2217 2222 1:CAS:528:DC%2BD3sXksVaktLg%3D 12798337
79. R Oltenfreiter L Staelens A Lejeune F Dumont F Frankenne JM Foidart, et al. 2004 New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents Nucl Med Biol 31 459 468 1:CAS:528:DC%2BD2cXjt1Sit7c%3D 15093816
80. R Oltenfreiter L Staelens U Hillaert A Heremans A Noel F Frankenne, et al. 2005 Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents Appl Radiat Isot 62 903 913 1:CAS:528:DC%2BD2MXjt1WrsbY%3D 15799868
81. QH Zheng X Fei X Liu JQ Wang KL Stone TD Martinez, et al. 2004 Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4-[11C]methoxyphenyl)sulfonyl]benzylamino]-3- methylbutanamide Nucl Med Biol 31 77 85 1:CAS:528:DC%2BD2cXltFWhtQ%3D%3D 14741572
82. R Oltenfreiter L Staelens S Labied V Kersemans F Frankenne A Noël, et al. 2005 Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents Cancer Biother Radiopharm 20 639 647 1:CAS:528:DC%2BD28XkvFyqtw%3D%3D 16398616
83. JD Hood DA Cheresh 2002 Role of integrins in cell invasion and migration Nat Rev Cancer 2 91 100 12635172
84. E Ruoslahti 2002 Specialization of tumour vasculature Nat Rev Cancer 2 83 90 12635171
85. T Taga A Suzuki I Gonzalez-Gomez FH Gilles M Stins H Shimada, et al. 2002 alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin Int J Cancer 98 690 697 1:CAS:528: DC%2BD38Xis1Wrurk%3D 11920637
86. K Dredge AG Dalgleish JB Marriott 2002 Recent developments in antiangiogenic therapy Expert Opin Biol Ther 2 953 966 1:CAS:528:DC%2BD3sXovFGr 12517273
87. E Ruoslahti MD Pierschbacher 1987 New perspectives in cell adhesion: RGD and integrins Science 238 491 497 1:CAS:528:DyaL1cXntVKkuw%3D%3D 2821619
88. M Aumailley M Gurrath G Müller J Calvete R Timpl H Kessler 1991 Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett 291 50 54 1:CAS:528:DyaK38XisVGh 1718779
89. RH Haubner HJ Wester WA Weber M Schwaiger 2003 Radiotracer-based strategies to image angiogenesis Q J Nucl Med 47 189 199 1:STN:280: DC%2BD3szmsVaisQ%3D%3D 12897710
90. B Indrevoll GM Kindberg M Solbakken E Bjurgert JH Johansen H Karlsen, et al. 2006 NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging Bioorg Med Chem Lett 16 6190 6193 1:CAS:528:DC%2BD28XhtF2jsrzP 17000103
91. TD Harris S Kalogeropoulos T Nguyen G Dwyer DS Edwards S Liu, et al. 2006 Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents Bioconjug Chem 17 1294 1313 1:CAS:528:DC%2BD28Xnsl2ru74%3D 16984141
92. GA Sulyok C Gibson SL Goodman G Holzemann M Wiesner H Kessler 2001 Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists J Med Chem 44 1938 1950 1:CAS:528: DC%2BD3MXjt1Sgtbk%3D 11384239
93. R Haubner B Kuhnast C Mang WA Weber H Kessler HJ Wester, et al. 2004 [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates Bioconjug Chem 15 61 69 1:CAS:528:DC%2BD3sXpslWns7Y%3D 14733584
94. T Poethko M Schottelius G Thumshirn M Herz R Haubner G Henriksen, et al. 2004 Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation Radiochim Acta 92 317 327 1:CAS:528:DC%2BD2cXmvVKlsbc%3D
95. T Poethko M Schottelius G Thumshirn U Hersel M Herz G Henriksen, et al. 2004 Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs J Nucl Med 45 892 902 1:CAS:528:DC%2BD2cXnsFygtLc%3D 15136641
96. 18F-labeling of N-amino-oxy derivatized peptides. Bioconjug Chem 2007;18:2085-9.
97. YS Lee JM Jeong HW Kim YS Chang YJ Kim MK Hong, et al. 2006 An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK) Nucl Med Biol 33 677 683 1:CAS:528:DC%2BD28XntFWrt7w%3D 16843843
98. M Glaser M Morrison M Solbakken J Arukwe H Karlsen U Wiggen, et al. 2008 Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups Bioconjug Chem 19 951 957 1:CAS:528:DC%2BD1cXjsVWgsb0%3D 18341272
99. O Prante J Einsiedel R Haubner P Gmeiner HJ Wester T Kuwert, et al. 2007 3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl phenylthiosulfonate: a thiol-reactive agent for the chemoselective 18F-glycosylation of peptides Bioconjug Chem 18 254 262 1:CAS:528:DC%2BD28XhtlCgs7%2FE 17226980
100. W Cai X Zhang Y Wu X Chen 2006 A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression J Nucl Med 47 1172 1180 1:CAS:528:DC%2BD28XnslSmt7w%3D 16818952
101. M Glaser M Solbakken DR Turton R Pettitt J Barnett J Arukwe, et al. 2009 Methods for 18F-labeling of RGD peptides: comparison of aminooxy [18F]fluorobenzaldehyde condensation with 'click labeling' using 2-[18F]fluoroethylazide, and S-alkylation with [18F]fluoropropanethiol Amino Acids 37 717 724 1:CAS:528:DC%2BD1MXhtFyqt7bK 19011732
102. H Kolb J Walsh Q Liang T Zhao D Gao J Secrest, et al. 2009 18F-RGD-K5: a cyclic triazole-bearing RGD peptide for imaging integrin avb3 expression in vivo J Nucl Med 50 Suppl 2 329
103. X Chen R Park M Tohme AH Shahinian JR Bading PS Conti 2004 MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide Bioconjug Chem 15 41 49 14733582
104. C Decristoforo I Hernandez Gonzalez J Carlsen M Rupprich M Huisman I Virgolini, et al. 2008 (68)Ga- and (111)In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression Eur J Nucl Med Mol Imaging 35 1507 1515 18369617
105. JM Jeong MK Hong YS Chang YS Lee YJ Kim GJ Cheon, et al. 2008 Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice J Nucl Med 49 830 836 1:CAS:528:DC%2BD1cXmvVSju7k%3D 18413379
106. KP Eisenwiener MI Prata I Buschmann HW Zhang AC Santos S Wenger, et al. 2002 NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors Bioconjug Chem 13 530 541 1:CAS:528:DC%2BD38XjtVaitr4%3D 12009943
107. P Knetsch M Petrik C Rangger M Fani A Helbok E von Guggenberg, et al. 2009 Ga-68 labelled RGD peptide for monitoring angiogenesis J Labelled Comp Radiopharm 52 S413
108. R Haubner HJ Wester WA Weber C Mang SI Ziegler SL Goodman, et al. 2001 Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 1781 1785 1:CAS:528:DC%2BD3MXit1Ohtbk%3D 11280722
109. R Haubner HJ Wester F Burkhart R Senekowitsch-Schmidtke W Weber SL Goodman, et al. 2001 Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 326 336 1:CAS:528:DC%2BD3MXhtlKmt7w%3D 11216533
110. R Haubner WA Weber AJ Beer E Vabuliene D Reim M Sarbia, et al. 2005 Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD PLoS Med 2 e70 15783258
111. C Hultsch M Schottelius J Auernheimer A Alke HJ Wester 2009 18)F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK) Eur J Nucl Med Mol Imaging 36 1469 1474 1:CAS:528:DC%2BD1MXps1Cktrc%3D 19350236
112. S Maschauer J Einsiedel R Haubner C Hocke M Ocker H Hübner, et al. 2010 Labeling and glycosylation of peptides using click chemistry: a general approach to (18)F-glycopeptides as effective imaging probes for positron emission tomography Angew Chem Int Ed Engl 49 976 979 1:CAS:528: DC%2BC3cXhtVGmt7Y%3D 20029856
113. JM Harris NE Martin M Modi 2001 Pegylation: a novel process for modifying pharmacokinetics Clin Pharmacokinet 40 539 551 1:CAS:528:DC%2BD3MXms1ars70%3D 11510630
114. JM Harris RB Chess 2003 Effect of pegylation on pharmaceuticals Nat Rev Drug Discov 2 214 221 1:CAS:528:DC%2BD3sXhsFKrtLs%3D 12612647
115. X Chen R Park AH Shahinian JR Bading PS Conti 2004 Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation Nucl Med Biol 31 11 19 1:CAS:528:DC%2BD2cXltFWhsw%3D%3D 14741566
116. X Chen R Park Y Hou V Khankaldyyan I Gonzales-Gomez M Tohme, et al. 2004 MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide Eur J Nucl Med Mol Imaging 31 1081 1089 1:CAS:528:DC%2BD2cXmtFWks7k%3D 15118844
117. X Chen Y Hou M Tohme R Park V Khankaldyyan I Gonzales-Gomez, et al. 2004 Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression J Nucl Med 45 1776 1783 1:CAS:528: DC%2BD2cXpslCqsLY%3D 15471848
118. Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ, et al. (18)F-Labeled Galacto and PEGylated RGD dimers for PET imaging of alpha(v)beta (3) integrin expression. Mol Imaging Biol 2009.
119. ML Janssen WJ Oyen I Dijkgraaf LF Massuger C Frielink DS Edwards, et al. 2002 Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model Cancer Res 62 6146 6151 1:CAS:528:DC%2BD38XosF2ms7w%3D 12414640
120. M Janssen WJ Oyen LF Massuger C Frielink I Dijkgraaf DS Edwards, et al. 2002 Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting Cancer Biother Radiopharm 17 641 646 1:CAS:528:DC%2BD3sXovVWmug%3D%3D 12537667
121. G Thumshirn U Hersel SL Goodman H Kessler 2003 Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation Chemistry 9 2717 2725 1:CAS:528: DC%2BD3sXltVSiurw%3D 12772286
122. X Chen M Tohme R Park Y Hou JR Bading PS Conti 2004 Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide Mol Imaging 3 96 104 1:CAS:528:DC%2BD2cXlvFCiu7s%3D 15296674
123. X Zhang Z Xiong Y Wu W Cai JR Tseng SS Gambhir, et al. 2006 Quantitative PET imaging of tumor integrin {alpha}v{beta}3 expression with 18F-FRGD2 J Nucl Med 47 113 121 1:CAS:528:DC%2BD28XhsFeisL4%3D 16391195
124. Z Wu ZB Li W Cai L He FT Chin F Li, et al. 2007 (18)F-labeled mini-PEG spacered RGD dimer ((18)F-FPRGD2): synthesis and microPET imaging of alpha(v)beta(3) integrin expression Eur J Nucl Med Mol Imaging 34 1823 1831 1:CAS:528:DC%2BD2sXhtFylu7%2FE 17492285
125. X Chen S Liu Y Hou M Tohme R Park JR Bading, et al. 2004 MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides Mol Imaging Biol 6 350 359 15380745
126. Y Wu X Zhang Z Xiong Z Cheng DR Fisher S Liu, et al. 2005 microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide J Nucl Med 46 1707 1718 1:CAS:528:DC%2BD28XitVGlt7o%3D 16204722
127. ZB Li W Cai Q Cao K Chen Z Wu L He, et al. 2007 (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression J Nucl Med 48 1162 1171 1:CAS:528:DC%2BD2sXhtVertL7F 17574975
128. L Sancey V Ardisson LM Riou M Ahmadi D Marti-Batlle D Boturyn, et al. 2007 In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer (99m)Tc-RAFT-RGD Eur J Nucl Med Mol Imaging 34 2037 2047 1:CAS:528:DC%2BD2sXhtlyiur%2FF 17674000
129. I Dijkgraaf AY Rijnders A Soede AC Dechesne GW van Esse AJ Brouwer, et al. 2007 Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes Org Biomol Chem 5 935 944 1:CAS:528:DC%2BD2sXisV2gt7Y%3D 17340009
130. TJ Wadas H Deng JE Sprague A Zheleznyak KN Weilbaecher CJ Anderson 2009 Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases J Nucl Med 50 1873 1880 1:CAS:528:DC%2BD1MXhsVyqs7rI 19875645
131. MS Morrison SA Ricketts J Barnett A Cuthbertson J Tessier SR Wedge 2009 Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy J Nucl Med 50 116 122 1:CAS:528:DC%2BD1MXhvFCjt7s%3D 19091899
132. AJ Beer R Haubner I Wolf M Goebel S Luderschmidt M Niemeyer, et al. 2006 PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression J Nucl Med 47 763 769 1:CAS:528:DC%2BD28XltFaiurw%3D 16644745
133. AJ Beer R Haubner M Sarbia M Goebel S Luderschmidt AL Grosu, et al. 2006 Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man Clin Cancer Res 12 3942 3949 1:CAS:528:DC%2BD28XmsValtLk%3D 16818691
134. AJ Beer AL Grosu J Carlsen A Kolk M Sarbia I Stangier, et al. 2007 [18F]Galacto-RGD positron emission tomography for imaging of {alpha}v{beta}3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 6610 6616 1:CAS:528:DC%2BD2sXhtlSmu7nO 18006761
135. O Schnell B Krebs J Carlsen I Miederer C Goetz RH Goldbrunner, et al. 2009 Imaging of integrin {alpha}v{beta}3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography Neuro Oncol 11 861 870 19401596
136. T Bach-Gansmo TV Bogsrud A Skretting 2008 Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692 Clin Physiol Funct Imaging 28 235 239 18384623
137. BJ McParland MP Miller TJ Spinks LM Kenny S Osman MK Khela, et al. 2008 The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers J Nucl Med 49 1664 1667 18794263
138. LM Kenny RC Coombes I Oulie KB Contractor M Miller TJ Spinks, et al. 2008 Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J Nucl Med 49 879 886 18483090
139. Winick J. A proof-of-concept study to assess the ability of [18F]AH-111585 PET imaging to detect tumours and angiogenesis. ClinicalTrials.gov 2007;November 28, 2007 ed: US National Institutes of Health.
140. HJ Cho JD Lee JY Park M Yun WJ Kang JC Walsh, et al. 2009 First in human
141. M Doss RK Alpaugh JQ Yu 2009 Biodistribution and radiation dosimetry of angiogenesis marker [18F]RGD-K5 measured using human PET J Nucl Med 50 Suppl 2 447
142. Zhang J. Efficacy study of [18F]RGD-K5 positron emission tomography (PET) as a tool to monitor response to an anti-angiogenic drug (K5-101). ClinicalTrials.gov 2009;October 1, 2009 ed: US National Institutes of Health.
143. Fanti S, Farsad M, Mansi L. PET-CT beyond FDG: a quick guide to image interpretation. 1st ed. Berlin: Springer; 2010.
144. MS Judenhofer HF Wehrl DF Newport C Catana SB Siegel M Becker, et al. 2008 Simultaneous PET-MRI: a new approach for functional and morphological imaging Nat Med 14 459 465 1:CAS:528:DC%2BD1cXktl2is7k%3D 18376410